Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

Through his X handler, Kamath revealed that he has been following the developments around Ozempic and GLP-1 drugs with some ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

We recently compiled a list of the 8 Best Pet Stocks to Buy According to Billionaires. In this article, we are going to take ...

The Prime Minister has suggested the US President is welcome to visit Australia despite previous disagreements over trade ...

Eli Lilly's CEO, David Ricks, reveals potential plans to manufacture the weight-loss drug Mounjaro in India as part of their global expansion.

The head of one of America's largest pharmaceutical companies says he does not support tariffs on Australian medicines as US President Donald Trump considers more trade restrictions.

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Eli Lilly CEO David Ricks reveals that developing a new drug costs around $4 billion before marketing. In an exclusive ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.